Nutlin-3

For research use only. Not for use in humans.

製品コードS1061

Nutlin-3化学構造

CAS No. 890090-75-2

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

サイズ 価格(税別)  
10mM (1mL in DMSO) JPY 32700
JPY 20200
JPY 30200
JPY 63400
JPY 163000
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

文献中Selleckの製品使用例(58)

製品安全説明書

Mdm2阻害剤の選択性比較

生物活性

製品説明 Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
ターゲット
Mdm2 [5]
(Cell-free assay)
180 nM
体外試験

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]
細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SMMC-7721  MX;GeY5kfGmxbjDBd5NigQ>? MYmxNEDPxE1? MV6zOkBp NU\yWlVVTE2VTx?= M{XxSIRwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ M4m1dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mki2N|EzLz5{NEK4OlMyOjxxYU6=
HuH-7 M2\Bc2Fxd3C2b4Ppd{BCe3OjeR?= MlzNNlAh|ryP NWrvfmhqPDhiaB?= MoKwSG1UVw>? MljabY5lfWOnczDhdI9xfG:|aYO= NIfWe5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK4OlMyOid-MkSyPFY{OTJ:L3G+
SMMC-7721  NGXqe4hCeG:ydH;zbZMhSXO|YYm= M{DaVlIxKM7:TR?= Mom3OFghcA>? M3Sy[WROW09? MVXpcoR2[2W|IHHwc5B1d3Orcx?= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ6NkOxNkc,OjR{OE[zNVI9N2F-
HuH-7 MYHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MU[xMlI2NTJyIN88US=> NXfWN2hrOjRxNEivO|IhcA>? MnO4SG1UVw>? MU\pcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= NFPKRWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK4OlMyOid-MkSyPFY{OTJ:L3G+
SMMC-7721  M4SxNWNmdGxiVnnhZoltcXS7IFHzd4F6 NEfzVo0yNjJ3LUKwJO69VQ>? NUPzTW57OjRxNEivO|IhcA>? MUXEUXNQ NFfP[YJqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> M3OybFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mki2N|EzLz5{NEK4OlMyOjxxYU6=
RKO M1L3ZmZ2dmO2aX;uJGF{e2G7 M3zjRlIxKM7:TR?= NUHPWJF[OjRiaB?= MmjybY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN4NkCwO{c,OjR|Nk[wNFc9N2F-
U2OS  MX7GeY5kfGmxbjDBd5NigQ>? NYPYSZFEOjBizszN MW[yOEBp MXLpcoR2[2W|IFjPMVEh\XiycnXzd4lwdiCjdDD0bIUhdGW4ZXygc4YhfHKjboPjdolxfGmxbh?= NF;TfVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO2OlAxPyd-MkSzOlYxODd:L3G+
RKO Ml;3SpVv[3Srb36gRZN{[Xl? Ml\qNlAh|ryP NHjmSI4zPCCq M2rxbolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBJVy1zIIDyc5RmcW5iYYOge4VtdCCjczD0bIUheDV|IIDyc5RmcW5? NFnveYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO2OlAxPyd-MkSzOlYxODd:L3G+
U2OS  NGO1Z|NHfW6ldHnvckBCe3OjeR?= NEmxRXQzOCEQvF2= NGXGc4szPCCq MX\pcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgTG8uOSCycn;0[YlvKGG|IIflcIwh[XNidHjlJJA2OyCycn;0[Ylv NHq5c|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO2OlAxPyd-MkSzOlYxODd:L3G+
MOLM MXvGeY5kfGmxbjDBd5NigQ>? MVGxNEDPxE1? MnraNlQhcA>? NVjWR3NyfXC{ZXf1cIF1\XNidHjlJHNQS1NvMTDlfJBz\XO|aX;u M3:y[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEezOVYzLz5{NES3N|U3OjxxYU6=
OCI NFPTRWFHfW6ldHnvckBCe3OjeR?= NHvHU3kyOCEQvF2= M3frcVI1KGh? MkPpeZBz\We3bHH0[ZMhfGinIGPPR3MuOSCneIDy[ZN{cW:w MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5M{W2Nkc,OjR2N{O1OlI9N2F-
BeWo M1jubGFxd3C2b4Ppd{BCe3OjeR?= MYGzNEDDvU1? MVSyOEBp NYn1cHpXcW6lcnXhd4V{KGGyb4D0c5Nqew>? M3nufFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEm4NVU1Lz5{NES5PFE2PDxxYU6=
BeWo M1\0[mZ2dmO2aX;uJGF{e2G7 NFfwc4M{OCEEtV2= NXuweJJOOjRiaB?= MmjCbY5kemWjc3XzJJA2OyxiTXTtNkwheDJzIHHu[EBRfW2jIHH0JJRp\SCycn;0[YlvKGyndnXs NWTVPIt5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PVgyPTRpPkK0OFk5OTV2PD;hQi=>
MOML13 NVnOXohoTnWwY4Tpc44hSXO|YYm= M{jOR|Ex|ryP NYDMO4VEOi92IHi= NHHWWWFqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> NYDnRYxjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OVk4PDlpPkK0OlU6PzR7PD;hQi=>
AML3 Ml:0SpVv[3Srb36gRZN{[Xl? M1W5RVEx|ryP MnjvNk81KGh? MlyxbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= NWTtcXVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OVk4PDlpPkK0OlU6PzR7PD;hQi=>
AML2 NVnQbWNqTnWwY4Tpc44hSXO|YYm= NEj2U3IyOM7:TR?= M2q1[FIwPCCq NUTNbW9EcW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM> NV7Leml{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OVk4PDlpPkK0OlU6PzR7PD;hQi=>
MOML13 MlW0RZBweHSxc3nzJGF{e2G7 M1vzd|IwOTBizszN NE\tdmozPC92ODDo MUnpcoR2[2W|IHHwc5B1d3Orcx?= MnOxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NUm3OFkoRjJ2NkW5O|Q6RC:jPh?=
AML2 MlTYRZBweHSxc3nzJGF{e2G7 MW[yM|ExKM7:TR?= M372XVI1NzR6IHi= NXXqWld1cW6mdXPld{BieG:ydH;zbZM> NIPSPIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[1PVc1QSd-MkS2OVk4PDl:L3G+
U2OS  M{nwNmZ2dmO2aX;uJGF{e2G7 NUHTXpBQOjBizszN NFvDSVAzPCCq NXrDdoJJcW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLiQlPMNmEyNCCEQ1zYUOKh[W6mQlPMWy=> NWX4cJhjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OlczPTlpPkK0PFY4OjV7PD;hQi=>
Hep3B MmHwRZBweHSxc3nzJGF{e2G7 MlfpbY5lfWOnczDhdI9xfG:|aYO= M122T|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEi0PFA6Lz5{NEi4OFgxQTxxYU6=
Huh-7 MXLBdI9xfG:|aYOgRZN{[Xl? NIq1c|BqdmS3Y3XzJIFxd3C2b4Ppdy=> M4\zUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEi0PFA6Lz5{NEi4OFgxQTxxYU6=
SMMC7721 Ml3ZRZBweHSxc3nzJGF{e2G7 MUjpcoR2[2W|IHHwc5B1d3Orcx?= NVr1PIgxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFQ5ODlpPkK0PFg1QDB7PD;hQi=>
HepG2 NF\BW2RCeG:ydH;zbZMhSXO|YYm= NFvlUlFqdmS3Y3XzJIFxd3C2b4Ppdy=> M17CWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEi0PFA6Lz5{NEi4OFgxQTxxYU6=
Hep3B NFznUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYS3NkBp MX;EUXNQ M4qxeWlEPTB;MkCuNVghyrFiMT64OEDPxE1? NXvkU2R5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFQ5ODlpPkK0PFg1QDB7PD;hQi=>
Huh-7 MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqzO|IhcA>? M2DidGROW09? NXvNcXdrUUN3ME2zN{46PiEEsTCzMlkh|ryP M3PvSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEi0PFA6Lz5{NEi4OFgxQTxxYU6=
SMMC7721/Ac MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nu[|czKGh? NHv6SG5FVVOR MX3JR|UxRTV3LkKxJOKyKDVwMEOg{txO NGLCbpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OFgxQSd-MkS4PFQ5ODl:L3G+
SMMC7721 M2LhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITLVZo4OiCq M{PGemROW09? NEXz[ZNKSzVyPUOxMlI5KMLzIESuNkDPxE1? MoDuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OES4NFkoRjJ2OEi0PFA6RC:jPh?=
HepG2/As NWntPHp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVK4TWZOPzJiaB?= NHHuOHFFVVOR Mm\6TWM2OD14OD6xN{DDuSB7Lk[g{txO MmHRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OES4NFkoRjJ2OEi0PFA6RC:jPh?=
HepG2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVK3NkBp NInJe4lFVVOR M4G3VmlEPTB;M{WuPFYhyrFiMj65JO69VQ>? M1HaSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEi0PFA6Lz5{NEi4OFgxQTxxYU6=
MOLM-13 MVzGeY5kfGmxbjDBd5NigQ>? NIXZW3M3yqEQvF2= MnS1OkBp M2PrZ2ROW09? NH[ySVNmdmijbnPld{B1cGViYXPleJlt[XSrb36gc4YhcGm|dH;u[UBJOkJiYX7kJIhm[XRic3jvZ4sheHKxdHXpcpMhUHOyMkegZY5lKEi|cEmw MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6NUC4Nkc,OjR6OEWwPFI9N2F-
MOLM-13 MUDGeY5kfGmxbjDBd5NigQ>? MlnFOuKh|ryP MYWwMVghcA>? MnjvSG1UVw>? NVqwRodNcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdFU{NCCPRF2yMEBxOjFiYX7kJIFk\XS7bHH0[YQheDV| MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6NUC4Nkc,OjR6OEWwPFI9N2F-
115 NIPHUlBHfW6ldHnvckBCe3OjeR?= M{jmPVUh|ryP NFrScYw1QCCq MnLZSG1UVw>? NViyOHNKcW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> M4j6fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
A498 NGn3[I5HfW6ldHnvckBCe3OjeR?= MXO1JO69VQ>? NI[4ZnQ1QCCq NX3kdFVbTE2VTx?= MUHpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi M3jXdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
Caki-2 MVvGeY5kfGmxbjDBd5NigQ>? MmrrOUDPxE1? NETjeWo1QCCq NHvHN5FFVVOR MX3pcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi NUDOc4VyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
ACHN M3;kW2Z2dmO2aX;uJGF{e2G7 NGfKZm02KM7:TR?= M{jKT|Q5KGh? Mo\LSG1UVw>? MoD4bY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= NW[zeW1JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
115 NWTGRlQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2T3b|Uh|ryP M4D3dlQ5KGh? NILKbJRFVVOR MmH0bY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg MorYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNke3PFcoRjJ3ME[3O|g4RC:jPh?=
A498 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLhOUDPxE1? NFO3NI81QCCq NVHYWIlmTE2VTx?= NFXUO|dqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> NWX4UWtmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
Caki-2 MlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzLOGQ2KM7:TR?= MXe0PEBp NWXMNW9oTE2VTx?= MWfpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= MmXkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNke3PFcoRjJ3ME[3O|g4RC:jPh?=
ACHN M17XUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M124O|Uh|ryP M3HtRlQ5KGh? NXzxToI5TE2VTx?= MVPpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= M1rrfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
115 NYfHZmdmTnWwY4Tpc44hSXO|YYm= NITteZIxNjVxMT:1JO69VQ>? M1;YXFQ5KGh? NHjETGpFVVOR NHHKbI5t\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= MljvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNke3PFcoRjJ3ME[3O|g4RC:jPh?=
A498 NIfNbJVHfW6ldHnvckBCe3OjeR?= NW\rVoNwOC53L{GvOUDPxE1? MkDxOFghcA>? NYOyNZRKTE2VTx?= Mme2cIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? NGPNW5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2O|c5Pyd-MkWwOlc4QDd:L3G+
Caki-2 MWPGeY5kfGmxbjDBd5NigQ>? NILGPW0xNjVxMT:1JO69VQ>? M2nvUlQ5KGh? MX3EUXNQ NGDQUG1t\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= MmX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNke3PFcoRjJ3ME[3O|g4RC:jPh?=
ACHN MmO2SpVv[3Srb36gRZN{[Xl? NELJXXMxNjVxMT:1JO69VQ>? NVqyVW9oPDhiaB?= MYnEUXNQ MYrs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4N{e4O{c,OjVyNke3PFc9N2F-
117 MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoTrNE42NTFyIN88US=> NX3YNWFNOC14IHS= NIm3SpNFVVOR NIfwbGpqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4DmWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[3O|g4Lz5{NUC2O|c5PzxxYU6=
115 NX2yPFZxS2WubDDWbYFjcWyrdImgRZN{[Xl? M3PXSFAvPS1zMDFOwG0> NX;JNHR1OC14IHS= MoDVSG1UVw>? M3fzc4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NX\3c4c6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
A498 NEm5SIhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYDxeXVLOC53LUGwJO69VQ>? NU\zS4pmOC14IHS= MUXEUXNQ M{O4UolvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NF32RVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2O|c5Pyd-MkWwOlc4QDd:L3G+
Caki-2 NUTycnNCS2WubDDWbYFjcWyrdImgRZN{[Xl? M{PT[VAvPS1zMDFOwG0> NFyzZ24xNTZiZB?= MYDEUXNQ MkPEbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NUfBVHZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
ACHN MlHCR4VtdCCYaXHibYxqfHliQYPzZZk> MWCwMlUuOTBizszN MnHKNE03KGR? M13wRWROW09? MUTpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYjvUnVkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlc4QDdpPkK1NFY4Pzh5PD;hQi=>
MCF7  NW\uVpBzTnWwY4Tpc44hSXO|YYm= MWmyMlUhyrWP MmewOFghcA>? MliySG1UVw>? MmD1[IVkemWjc3XzJJRp\SCqb33vcI9od3W|IFTTRkBz\XCjaYKg[pJmeXWnbnPp[ZM> NX\pV|R7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwPFU6ODJpPkK1NFg2QTB{PD;hQi=>
MCF7  MX\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4TvPVIvPSEEtV2= MWi1JIQ> MoLrSG1UVw>? NVTQfZl5e2Wwc3n0bZpmeyCPQ1[3JJRwKFCDUmCgbY5pcWKrdHnvci=> M4\xOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEi1PVAzLz5{NUC4OVkxOjxxYU6=
RAW 264.7 NF\acohHfW6ldHnvckBCe3OjeR?= M2LKTlExyqEQvF2= M4P2Z|MxKG2rbh?= NXT2Z3licW6qaXLpeJMhVFCVLXnu[JVk\WRiTl:gdJJw\HWldHnvcuKh NHHKTIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG3NlU1Pyd-MkWxO|I2PDd:L3G+
RAW 264.7 NWfvWZQzTnWwY4Tpc44hSXO|YYm= NVy3T3gzOTEEoN88US=> M3[2fVMxKG2rbh?= M1;yNJJm\HWlZYOgeIhmKEySUz3heYdu\W62ZXSgeIhmKE6ILd86RkBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZYN1cX[rdIm= NXXDZnhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxO|I2PDdpPkK1NVczPTR5PD;hQi=>
RAW 264.7 NGHvSmtHfW6ldHnvckBCe3OjeR?= NX31SHVTOTEEoN88US=> MoPBN|AhdWmw M3G3fpBz\X[nboTzJJRp\SCyNUOgdoVlfWO2aX;uJIlvKHKnc4DvcpNmKHSxIFzQVy=> NEfhV|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG3NlU1Pyd-MkWxO|I2PDd:L3G+
SUM102PT Ml\YSpVv[3Srb36gRZN{[Xl? NVzPNWx{OTEEoN88US=> MmnSNlQhcA>? MX3EUXNQ NH7JboRqdmirYnn0d{AhXEeILd8yN{1qdmS3Y3XkJGVRUEJ{wrDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= NH7qN|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK1O|czQSd-MkWyOVc4Ojl:L3G+
SK-BR-7 MXTGeY5kfGmxbjDBd5NigQ>? NVnDd4FbOTEEoN88US=> Mo\QNlQhcA>? NX3NZYNHTE2VTx?= MXnpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? Mn62QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NUe3NlkoRjJ3MkW3O|I6RC:jPh?=
MCF-10CA1a MV\GeY5kfGmxbjDBd5NigQ>? M1r2SVExyqEQvF2= M4PkWFI1KGh? NV[3dpZ5TE2VTx?= NXjkNXI5cW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u NW\nVVVTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOVc4OjlpPkK1NlU4PzJ7PD;hQi=>
MCF-10CA1a M1jCW2Z2dmO2aX;uJGF{e2G7 NF7C[lMyOMLizszN MkHGNlQhcA>? M4\3PWROW09? MYTk[YNz\WG|ZYOgeIhmKFSJRj5OtlMucW6mdXPl[EBuWk6DIHzleoVteyCxZl3NVFItyqCPTWC5MEBidmUEoHnueIVoemmwwrFOtuKhOw>? MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ3N{eyPUc,OjV{NUe3Nlk9N2F-
MCF-10A1  MWfGeY5kfGmxbjDBd5NigQ>? M{nOWVExyqEQvF2= NWfnOFZNOjRxNEigbC=> NWmyTpFRTE2VTx?= NX\hb3RicW6qaXLpeJMhdWmpcnH0bY9vKG:oIH7vdo1idCCkcnXhd5Qh\XCrdHjlcIlidMLi MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ3N{eyPUc,OjV{NUe3Nlk9N2F-
MCF-10CA1a MX;GeY5kfGmxbjDBd5NigQ>? NHu0XWEyOMLizszN Mmj0OFghcA>? M1LSSmROW09? NFTvbItqdmirYnn0d{Bj[XOjbDDpcpZie2mxbjDhcoQhemWmdXPl[EBVT0ZvzsKzMYlv\HWlZXSgbY53[XOrb36geI8h[mG|YXygcIV3\Wy| MnqyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NUe3NlkoRjJ3MkW3O|I6RC:jPh?=
HCT116  NGLiO2JHfW6ldHnvckBCe3OjeR?= NVz0RZFoOTBiwsXN M{LUV|I1KGh? NVLDUXk4[2G3c3XzJIEheDV|LXTldIVv\GWwdDD0[ZRz[XCub3nkJGcyNWG{cnXzeEBqdiCmaYDsc4llKEiFVEGxOkBkdG:wZYOgSFMh[W6mIFS4 NXvSVHdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPFAxPTVpPkK1N|gxODV3PD;hQi=>
A2780 M{n3cmZ2dmO2aX;uJGF{e2G7 M2S0UlExyqEQvF2= NGHxbnIzOWkEoB?= NYjNeXRxTE2VTx?= NIPmWotl\WO{ZXHz[ZMhfGinIF\vfG0yKGyndnXsdy=> NV7DWYtERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NlY2PDhpPkK1OFI3PTR6PD;hQi=>
NCI-H23 Ml7VSpVv[3Srb36gRZN{[Xl? MmLGNVDDqM7:TR?= MlTmNlFpyqB? NUPQe2RsTE2VTx?= M1zIOIRm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzz NFLDfJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSyOlU1QCd-MkW0NlY2PDh:L3G+
A2780 NX\JcmpITnWwY4Tpc44hSXO|YYm= M32yfVExyqEQvF2= NH;6UYQzOWkEoB?= M2nuemROW09? MoXCbY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR{NkW0PEc,OjV2Mk[1OFg9N2F-
NCI-H23 MVjGeY5kfGmxbjDBd5NigQ>? M{e0b|ExyqEQvF2= MUGyNYjDqA>? NFrkclVFVVOR NFLkR4RqdmO{ZXHz[ZMheDV|IIDyc5RmcW5ibHX2[Yx{ M2XCTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEK2OVQ5Lz5{NUSyOlU1QDxxYU6=
OVCAR10 M2nLVmZ2dmO2aX;uJGF{e2G7 MY[xNOKh|ryP MoHaNlFpyqB? NGHnSIpFVVOR MnvJbY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> NVG0NHNyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NlY2PDhpPkK1OFI3PTR6PD;hQi=>
MCF-7 NE\ve2FHfW6ldHnvckBCe3OjeR?= M2\hSFExyqEQvF2= NHLlc2ExNTJ2IHi= MYjpcoR2[2W|IIC1N{BidmRicEKxM2NqeDF? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR6MkO3N{c,OjV2OEKzO|M9N2F-
SMMC-7721 M1fPbGZ2dmO2aX;uJGF{e2G7 MkDkNVAh|ryP MlLWN|YhcA>? M1S4dmROW09? Mlj3Z4F2e2W|IITo[UBm[3SxcHnjJIV5eHKnc4Ppc44hd2ZiSV\JNVY> NH7QZpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW0OFM3OSd-MkW1OFQ{PjF:L3G+
SMMC-7721 NV[4dY85TnWwY4Tpc44hSXO|YYm= MmSxNVAh|ryP NUTyeXBGPDhiaB?= MWDEUXNQ NYPZOpVqcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mxsBKTk6EMdMgcXJPSQ>? NHXD[I49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW0OFM3OSd-MkW1OFQ{PjF:L3G+
SMMC-7721 NXHWXXFKTnWwY4Tpc44hSXO|YYm= NUDqOY9kOTBizszN MmTrOFghcA>? M3XEWWROW09? MojTbY5lfWOnczD0bIUh[2i{b33heIlvNWKxdX7kJJBzd3SnaX6gTWZKOTZidH:gdIFzfGmjbHz5JIxw[2GuaYrlJIlvKHSqZTDjfZRweGyjc35CpC=> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV2NEO2NUc,OjV3NESzOlE9N2F-
SMMC-7721 NGP2U5RHfW6ldHnvckBCe3OjeR?= NF\BdYoyOCEQvF2= NV3UdpNPPDhiaB?= M3fye2ROW09? M1q1XINifXOnczDEUmEhTFOEIHThcYFo\Q>? MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV2NEO2NUc,OjV3NESzOlE9N2F-
DU4475  NYnDdoNDTnWwY4Tpc44hSXO|YYm= NX;3Xow6PS9zMD:yNEDPxE1? NGrHXYQzPMLiaB?= MVjkc5dvemWpdXzheIV{KFSxY3GtNUBld3OnIHTldIVv\GWwdHz5 MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV2N{G3OEc,OjV3NEexO|Q9N2F-
MCF-7  NU\jRpZ{TnWwY4Tpc44hSXO|YYm= MYixNOKh|ryP NX;FSWdtTE2VTx?= NY[3e5FvcW6qaXLpeJMh[3mlbHnuJGQyKGGwZDDEbYNmesLi MkG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MEK3NFMoRjJ3N{CyO|A{RC:jPh?=
C2C12 MnLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV2xNOKh|ryPwrC= NX;4SXBIOjRxNEivO|IhcA>? M2XWSmROW09? NVTuPZpWcW6qaXLpeJMh[2WubIOgdJJwdGmoZYLheIlwdiCjbnSg[Iln\mW{ZX70bYF1cW:w MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5MUe5OEc,OjV6N{G3PVQ9N2F-
L6 MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYWxNOKh|ryPwrC= Mkn1NlQwPDhxN{KgbC=> NVzld5V6TE2VTx?= MmXjbY5pcWKrdIOgZ4VtdHNicILvcIln\XKjdHnvckBidmRiZHnm[oVz\W62aXH0bY9v NHy0VVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3NVc6PCd-MkW4O|E4QTR:L3G+
CRL-5908 MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEK1V44zPCCq MXzJR|UxRTN6LkexJOKyKDJwNEOg{txO Ml\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMkWyN|AoRjJ4MUK1NlMxRC:jPh?=
A549-920 NIDGTnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXZZlUzPCCq MmrITWM2OD1|Mz64OUDDuSB2Lki0JO69VQ>? MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{NUKzNEc,OjZzMkWyN|A9N2F-
A549-NTC NXPkVYpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInjWYMzPCCq NFHORmpKSzVyPUG5MlQzKMLzIEGuPVYh|ryP MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{NUKzNEc,OjZzMkWyN|A9N2F-
A549 M1\L[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV:yOEBp MUXJR|UxRTF5Lk[4JOKyKDRwNUKg{txO M3L1S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUK1NlMxLz5{NkGyOVI{ODxxYU6=
C666-1 NUjj[WpYSXCxcITvd4l{KEG|c3H5 NG\HO3IyOCEEtV2= MkHCOFgwPzJiaB?= MoezSG1UVw>? MUPz[Y5{cXSrenXzJGM3PjZvMTDj[YxteyC2bzDjbZNxdGG2aX6tbY5lfWOnZDDhdI9xfG:|aYO= NYO1bIcyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVI2PzVpPkK2NlUzPTd3PD;hQi=>
C666-1  M{TTcGZ2dmO2aX;uJGF{e2G7 NITUWnkyOCEEtV2= NHX4U3gzPCCq MYnEUXNQ MU\hZ5RqfmG2ZYOgeIhmKHB3MzDwZZRpf2G7LDD1dJJm\3WuYYTpcocheDV|LDDwNlEh[W6mIF3kcVI> NYTaRmNYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVI2PzVpPkK2NlUzPTd3PD;hQi=>
C666-1 MV7D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYPNOXdGOTBiwsXN M{C5WlQ5KGh? MV\EUXNQ NEn5U2J{\W6|aYTpfoV{KEN4Nk[tNUBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDjbZNxdGG2aX6= NWTU[WN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVI2PzVpPkK2NlUzPTd3PD;hQi=>
C666-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfmbYhKSzVyPUG5Mlk2yrF6LkmzJO69VQ>? NX\nRlhYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVI2PzVpPkK2NlUzPTd3PD;hQi=>
NP460 NELk[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJ{Lki1xtEyNjF6IN88US=> MoDKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUK1O|UoRjJ4MkWyOVc2RC:jPh?=
NP69 NY\xdJk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\6WGlEPTB;M{GuOlnDuTJwNUSg{txO MoC2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUK1O|UoRjJ4MkWyOVc2RC:jPh?=
MCF7 MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Hi[|XDqM7:TR?= NU\NRXB{PDkEoHi= NYD6WZpW[myxY3vzJFI4NU:KQz3pcoR2[2WmIHPlcIwheHKxbHnm[ZJifGmxbjDjc41x[XKjYnzlJJRwKHSqYYSgc4Yh[mG|YXygcIV3\Wy| M1LiXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{WwOVY2Lz5{NkO1NFU3PTxxYU6=
HuH-7 MWDGeY5kfGmxbjDBd5NigQ>? NY\yUo9TOTBizszN M{nDZ|M3KGh? NEfH[JhFVVOR NIHuRVdld3ewLYLl[5Vt[XSnczD0bIUheHKxdHXpckBmgHC{ZYPzbY9vKGyndnXsJI9nKHCqb4PwbI8uW2W{M{myMZA2Ow>? NUDVUGh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPFY{OTJpPkK0Nlg3OzF{PD;hQi=>
AT2 MmD0SpVv[3Srb36gRZN{[Xl? MUO1M|ExKM7:TR?= NF\2UpFt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= NWT6[2ZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFAzODNpPkK0NlQxOjB|PD;hQi=>
REH MVvGeY5kfGmxbjDBd5NigQ>? MYC1M|ExKM7:TR?= NHjVNY9t\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= NXHUXW1pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFAzODNpPkK0NlQxOjB|PD;hQi=>
UoCB6 MXTGeY5kfGmxbjDBd5NigQ>? NFXaPGk2NzFyIN88US=> NHrCU|dt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2MEKwN{c,OjR{NECyNFM9N2F-
AT2 M4n3SGNmdGxiVnnhZoltcXS7IFHzd4F6 NUHUUm9QOC1{NTFOwG0> M2Ht[olvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MmjrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NECyNFMoRjJ2MkSwNlA{RC:jPh?=
REH MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1W5bVAuOjVizszN MoPUbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MoPjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NECyNFMoRjJ2MkSwNlA{RC:jPh?=
UoCB6 MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYiwMVI2KM7:TR?= NYj6WYhEcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M{nHOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkSwNlA{Lz5{NEK0NFIxOzxxYU6=
A2780 MWrGeY5kfGmxbjDBd5NigQ>? MnWyOU8yOC9{MDFOwG0> MlXCNlQhcA>? MlvzeZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF|NkG0O{c,OjRzM{[xOFc9N2F-
H460 NWO3eYtPTnWwY4Tpc44hSXO|YYm= NYG2SYtSPS9zMD:yNEDPxE1? MmTUNlQhcA>? NX\uPZJ[fXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC= NX\aT3B4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN|YyPDdpPkK0NVM3OTR5PD;hQi=>
Lovo  MXzGeY5kfGmxbjDBd5NigQ>? M33CO|UwOTBxMkCg{txO MoTaNlQhcA>? NYS4RmFvfXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC= M4LuVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUO2NVQ4Lz5{NEGzOlE1PzxxYU6=
A2780 NGrOfmVCeG:ydH;zbZMhSXO|YYm= MnztOU8yOC9{MDFOwG0> MlrONlQhcA>? M3HiVIVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN M1PvNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUO2NVQ4Lz5{NEGzOlE1PzxxYU6=
H460 NEXPclNCeG:ydH;zbZMhSXO|YYm= MnTrOU8yOC9{MDFOwG0> MUSyOEBp M3ewXYVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN M1jMZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUO2NVQ4Lz5{NEGzOlE1PzxxYU6=
Lovo  M37WSWFxd3C2b4Ppd{BCe3OjeR?= M2WzW|UwOTBxMkCg{txO NVTPU5lKOjRiaB?= MkPa[Y5p[W6lZYOgZZBweHSxc3nzJIlv\HWldHnvckBjgSCGMk[5TE9GOTl3UjDveoVzKHKqVGLBTWw> M4PKcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUO2NVQ4Lz5{NEGzOlE1PzxxYU6=
U87MG MnvvSpVv[3Srb36gZZN{[Xl? NETXWYIyOCCvaX7z NXjTXXVpSmmwZHnu[{Bi\m[rbnn0fUB1dyCPRF2yJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhVUSPMj;wOVMheHKxdHXpckBqdnSncnHjeIlwdiCjZoTldkAyOCCvaX7zJIJ6KHG3YX70bZRifGm4ZTDzZY5lf2mlaDDpcY12dm9iYYPzZZktKEmFNUCgQUAxNjFyNEWg{txONg>? NUDFd|hiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewOVA4QDJpPkK3NFUxPzh{PD;hQi=>
U87MG M3vjWmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MXe0PEBpenN? NEftWGZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW4O21IKGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKHB3MzDh[pRmeiB2ODDodpMh[nliTWTTJIF{e2G7LDDJR|UxKD1iNj61JO69VS5? NX31ZoRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewOVA4QDJpPkK3NFUxPzh{PD;hQi=>
U343MG M3qwZWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M2e2PVQ5KGi{cx?= MUDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFV|NEPNS{Bk\WyuczDlfJBz\XO|aX7nJJdqdGRidInw[UBxPTNiYX\0[ZIhPDhiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDF{Lk[g{txONg>? MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB3MEe4Nkc,OjdyNUC3PFI9N2F-
SW620 M1LXRWN6fG:2b4jpZ4l1gSCjc4PhfS=> NYnQeYRuPzJiaILz NHe4fWpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUXzZ{MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5|ODFOwG0v M{PreVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE6OTN|ND:nQmNpTU2ETEyvZV4>
A549 M1vmWWN6fG:2b4jpZ4l1gSCjc4PhfS=> MnPYO|IhcHK| NHj4bZBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjRzIN88UU4> MnXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVkyOzN2Lze+R4hGVUKOPD;hQi=>
SJSA1 M2HCcGN6fG:2b4jpZ4l1gSCjc4PhfS=> Mn\PO|IhcHK| MoHER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2pUSTFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFEvQDFizszNMi=> NGrUVpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQTF|M{SvK|5EcEWPQly8M4E,
HCT116 Mmq2R5l1d3SxeHnjbZR6KGG|c3H5 MmPMO|IhcHK| M{L5U2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hPC54MzFOwG0v NHzjPI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQTF|M{SvK|5EcEWPQly8M4E,
PC3 MVnDfZRwfG:6aXPpeJkh[XO|YYm= M4K4SlczKGi{cx?= NInyPFFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFYvOzdizszNMi=> MnqzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVkyOzN2Lze+R4hGVUKOPD;hQi=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
MDM2 / p53 / ALKBH2 / p21 / PUMA; 

PubMed: 23258843     


CCF-STTG1 cells were treated with the MDM2 antagonist nutlin-3 (0–8 µM) for 24h before cell lysates were collected for western blotting.

RRM1 / RRM2 / p53R2 / p21 / p53 / pS6 / S6; 

PubMed: 28507282     


(A) Rh18 cells were treated with different concentrations of nutlin-3 as indicated for 24 hr. Total proteins were extracted for immunoblotting of RRM1, RRM2, γH2AX, p21, p53R2, p53, S6, pS6-235/6 and 4E-BP1. (B) Rh30 cells were treated with different concentrations of nutlin-3 as indicated for 24 hr. Total proteins were extracted for immunoblotting of RRM1, RRM2, γH2AX, p21, p53R2, p53, S6, pS6-235/6 and 4E-BP1. GAPDH and Actin served as loading controls.

23258843 28507282
Immunofluorescence
Lamin A / Lamin C / p16 / H3K9me3; 

PubMed: 30728349     


c Immunofluorescence images of nuclear deformation and p16 expression after Nutlin-3 treatment for different time period. HCT p53+/− cells were treated with Nutlin-3 (1 μM) for different time (24, 48 h). After treatment, cells were subjected to immunofluorescence staining for Lamin A/C (Red), p16 (Green), and counterstained with DAPI (Blue). dImmunofluorescence images of nuclear deformation and decreased expression of H3K9me3 in HCT p53+/− cells (left). Counting of histone H3K9me3-positive cells (middle) and signal intensities (right) on the basis of IF staining. HCT p53+/− cells were treated with Nutlin-3 (1 μM) for different time (24, 48 h). After treatment, cells were IF stained with Lamin A/C (Red), H3K9me3 (Green), and counterstained with DAPI (Blue). *P < 0.05. 

Merlin / cyclin D1 / p53 / MDM2; 

PubMed: 30274821     


The changes in the subcellular localization of proteins in response to Nutlin-3. Nuclear merlin was indicated with white arrows. Scale bar = 50 μm.

p53; 

PubMed: 24286312     


The subcellular localization of p53 was detected under immunofluorescence microscope (1,000×). The cells were treated as indicated and stained for p53 (red). Nuclei were counterstained with DAPI (blue).

30728349 30274821 24286312
Growth inhibition assay
Cell viability; 

PubMed: 29286113     


Inhibitory effect of nutlin-3 for the cell proliferation after cultivate cells at different concentration for three times (24, 48 and 72 h), respectively.

29286113
体内試験 Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

お薦めの試験操作（参考用のみ）

キナーゼ試験：

[1]
- 合併

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
細胞試験：

[1]
- 合併
  • 細胞株： HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • 濃度： Dissolved in DMSO, final concentrations ~ 30 μM
  • 反応時間： 8, 24, and 48 hours
  • 実験の流れ：

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (参考用のみ)
動物試験：

[1]
- 合併
  • 動物モデル： Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • 投薬量： 200 mg/kg
  • 投与方法： Orally, twice a day
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 581.5
化学式

C30H30Cl2N4O4
CAS No. 890090-75-2
Storage powder
in solvent
別名 N/A
Smiles CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）
投与量 mg/kg 動物平均体重 g 投与体積（動物毎） ul 動物数 匹
ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

総分子量：g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問（FAQ）

  • 質問1：

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • 回答：

    It is a racemate.

selleck catalog

Mdm2シグナル伝達経路

相関Mdm2製品

  • Idasanutlin (RG-7388)

    Idasanutlin (RG-7388) is a potent and selective p53-MDM2 inhibitor with IC50 of 6 nM showing improved in vitro binding as well as cellular potency/selectivity.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • NSC 207895

    NSC 207895 (XI-006) suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.

  • Nutlin-3a

    Nutlin-3a ((-)-Nutlin-3), the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner.

    Features:Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.

  • Nutlin-3b

    Nutlin-3b ((+)-Nutlin-3) is a p53/MDM2 antagonist or inhibitor with IC50 value of 13.6 μM, 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite (-)-enantiomer Nutlin-3a.

  • YH239-EE

    YH239-EE, the ethyl ester of YH239, is a potent p53-MDM2 antagonist and an apoptosis inducer.

Tags: Nutlin-3を買う | Nutlin-3 ic50 | Nutlin-3供給者 | Nutlin-3を購入する | Nutlin-3費用 | Nutlin-3生産者 | オーダーNutlin-3 | Nutlin-3化学構造 | Nutlin-3分子量 | Nutlin-3代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID